Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Non Operating Income (2016 - 2025)

IGC Pharma has reported Non Operating Income over the past 12 years, most recently at $1.1 million for Q3 2025.

  • Quarterly Non Operating Income rose 2406.98% to $1.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Sep 2025, up 1548.0% year-over-year, with the annual reading at $325000.0 for FY2025, 127.27% up from the prior year.
  • Non Operating Income was $1.1 million for Q3 2025 at IGC Pharma, up from $306000.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $1.1 million in Q3 2025 and troughed at $4000.0 in Q3 2021.
  • The 5-year median for Non Operating Income is $32000.0 (2023), against an average of $127631.6.
  • Year-over-year, Non Operating Income tumbled 96.16% in 2022 and then soared 2971.43% in 2025.
  • A 5-year view of Non Operating Income shows it stood at $4000.0 in 2021, then surged by 625.0% to $29000.0 in 2022, then grew by 10.34% to $32000.0 in 2023, then soared by 53.12% to $49000.0 in 2024, then surged by 2100.0% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Non Operating Income are $1.1 million (Q3 2025), $306000.0 (Q2 2025), and $215000.0 (Q1 2025).